Frazier Lifesciences Acquisition Corporation Stock
Stocks
NAMS
NL00150012L7
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
08:05:05 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 21.64 EUR | -13.18% |
|
-8.85% | -28.96% |
| 08-26 | NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026 | CI |
| 08-14 | Newamsterdam Pharma Company N.V. Announces Executive Changes | CI |
| Market Cap | 2.57B 2.98B 2.42B 2.2B 4.14B 283B 4.16B 28.57B 11.12B 144B 11.18B 10.94B 477B | P/E 2026 * |
-13.1x | P/E 2027 * | -14x |
|---|---|---|---|---|---|
| Enterprise Value | 2.15B 2.49B 2.02B 1.84B 3.46B 236B 3.48B 23.86B 9.29B 120B 9.34B 9.14B 398B | EV / Sales 2026 * |
87.2x | EV / Sales 2027 * | 16.5x |
| Free-Float |
99.11% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Frazier Lifesciences Acquisition Corporation
| 1 day | -13.18% | ||
| 1 week | -8.85% | ||
| Current month | -1.66% | ||
| 1 month | -10.33% | ||
| 3 months | -21.61% | ||
| 6 months | -29.72% | ||
| Current year | -28.96% |
| 1 week | 24.8 |  | 27.6 |
| 1 month | 24.8 | | 28.97 |
| Current year | 24.8 | | 42.2 |
| 1 year | 23.05 | | 42.2 |
| 3 years | 5.63 | | 42.2 |
| 5 years | 5.63 | | 42.2 |
| 10 years | 5.63 | | 42.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Davidson
CEO | Chief Executive Officer | 69 | 2022-10-31 |
Mayur Somaiya
DFI | Director of Finance/CFO | 52 | 2023-10-22 |
John Kastelein
CTO | Chief Tech/Sci/R&D Officer | 72 | 2022-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Davidson
BRD | Director/Board Member | 69 | 2022-10-31 |
John Kastelein
BRD | Director/Board Member | 72 | 2022-10-31 |
James Topper
BRD | Director/Board Member | 64 | 2022-10-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/24/26 | Futurum BV
| Exercice | Company | 375,000 | 0.3208% | |
| 8/24/26 | Other | Chief Technology Officer | 0 | 0% | ||
| 7/20/26 | Exercice | Controller/Auditor | 315,000 | 0.2695% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.18% | -8.85% | +3.62% | +138.93% | 2.98B | |
| -0.25% | -4.10% | +38.38% | +92.61% | 68.21B | |
| +1.81% | +0.49% | +48.84% | +89.93% | 64.25B | |
| -0.25% | -1.92% | -10.72% | +436.70% | 26.54B | |
| +0.33% | -10.61% | +1.95% | -16.27% | 25.61B | |
| +1.96% | +1.44% | +32.57% | -17.76% | 19.88B | |
| -6.09% | -12.08% | +226.11% | +375.00% | 17.13B | |
| +0.65% | -5.28% | -1.12% | +534.90% | 14.93B | |
| +4.12% | +0.30% | +52.03% | +150.18% | 14.1B | |
| -0.24% | +5.18% | +23.04% | +190.97% | 12.45B | |
| Average | -1.12% | -4.44% | +41.47% | +197.52% | 26.61B | |
| Weighted average by Cap. | +0.22% | -3.29% | +41.55% | +158.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.62M 28.54M 23.16M 21.1M 39.68M 2.71B 39.89M 274M 107M 1.38B 107M 105M 4.57B | 122M 141M 115M 105M 197M 13.42B 198M 1.36B 528M 6.83B 531M 519M 22.63B |
| Net income | -202M -234M -190M -173M -326M -22.24B -328M -2.25B -875M -11.31B -880M -861M -37.51B | -195M -226M -183M -167M -314M -21.43B -316M -2.17B -843M -10.9B -848M -829M -36.15B |
| Net Debt | -424M -491M -399M -363M -683M -46.61B -686M -4.71B -1.83B -23.71B -1.84B -1.8B -78.62B | -556M -645M -523M -477M -897M -61.22B -901M -6.19B -2.41B -31.14B -2.42B -2.37B -103B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-31 | €24.92 | -1.66% | 714,352 |
| 26-08-31 | €25.34 | -2.16% | 1,546,249 |
| 26-08-28 | €25.90 | -3.32% | 1,036,086 |
| 26-08-27 | €26.79 | -2.23% | 626,831 |
| 26-08-26 | €27.40 | +0.22% | 758,725 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NAMS Stock
Select your edition
All financial news and data tailored to specific country editions
